Article content material
License settlement gives Université de Montréal entry to CRISPR gene enhancing expertise to be used throughout its platform companies
DUBLIN & MONTREAL — ERS Genomics Restricted (‘ERS’), the CRISPR licensing Firm, and Université de Montréal (‘UdeM’), a number one Canadian analysis establishment famend for scientific innovation and expertise switch, immediately introduced a non-exclusive CRISPR/Cas9 license settlement.
The settlement grants the college entry to ERS’ CRISPR/Cas9 patent portfolio – together with enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM’s Institute for Analysis in Immunology and Most cancers.
Article content material
Lynda Adam, PhD, Director of Know-how Switch, Innovation and Partnerships, Université de Montréal, mentioned: “With the acquisition of this license, we now have launched platform companies that can broaden entry to genome-wide CRISPR screening and information to the analysis group. Moreover, this license allows UdeM researchers to hold out challenge collaborations and partnerships utilizing CRISPR expertise underneath sure situations.”
John E. Milad, CEO, ERS Genomics, commented: “Université de Montréal has a repute for making excellent contributions to scientific innovation. Offering this license and entry to the CVC patent portfolio has enabled the launch of screening platforms which can play a job in uncovering new therapeutic targets and finally enhance healthcare outcomes. We look ahead to seeing the transformative affect of their work on international medical challenges.”
CRISPR gene enhancing is a genetic engineering method in molecular biology by which the genomes of residing organisms could also be modified. It’s primarily based on a simplified model of the bacterial CRISPR-Cas9 antiviral defence system. The event of the method earned biochemists Emmanuelle Charpentier (one of many founders of ERS Genomics) and Jennifer Doudna the Nobel Prize in Chemistry in 2020.
ERS Genomics gives licensing to CRISPR/Cas9 expertise for corporations interested by pursuing its use of their industrial applications. Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 utilization in all cells, together with micro organism, archaea, yeasts, and algae. ERS Genomics licenses these patents by way of its direct license from Emmanuelle Charpentier and now has almost 150 licenses in place worldwide.
Monetary particulars of the settlement aren’t disclosed.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241001142132/en/
Contacts
Dr Ben Rutter
E-mail: ben.rutter@zymecommunications.com
#distro
Share this text in your social community